Reasons for next-line therapy after daratumumab
| . | Events (n = 21) . |
|---|---|
| Increasing dFLC, n (%) | 10 (48) |
| dFLC at TTNT, median (IQR), mg/dL | 5.2 (3.1-9.6) |
| Meeting criteria for >50% increase from nadir and dFLC > 2 mg/dL, n | 8 |
| Meeting Pavia high-risk dFLC progression criteria,20 n | 2 |
| Insufficient hematologic response, n (%) | 8 (38) |
| dFLC at TTNT, median (IQR), mg/dL | 5.95 (3.1-16.9) |
| Continued or worsening organ dysfunction, n (%) | 2 (10) |
| Decision for consolidative autologous transplant, n (%) | 1 (5) |
| . | Events (n = 21) . |
|---|---|
| Increasing dFLC, n (%) | 10 (48) |
| dFLC at TTNT, median (IQR), mg/dL | 5.2 (3.1-9.6) |
| Meeting criteria for >50% increase from nadir and dFLC > 2 mg/dL, n | 8 |
| Meeting Pavia high-risk dFLC progression criteria,20 n | 2 |
| Insufficient hematologic response, n (%) | 8 (38) |
| dFLC at TTNT, median (IQR), mg/dL | 5.95 (3.1-16.9) |
| Continued or worsening organ dysfunction, n (%) | 2 (10) |
| Decision for consolidative autologous transplant, n (%) | 1 (5) |